Loading... Please wait...

Our Newsletter

GSK1120212 (Trametinib) | MEK1/2 inhibitor

  • GSK1120212 (Trametinib).jpg
  • GSK1120212 (Trametinib), 400x400px, png
Catalog #:

Product Description

Trametinib (GSK1120212) is an orally-available, tetrahydropyridopyrimidine-based, allosteric inhibitor of MEK1 and MEK2, with an IC50 of 1.6 and 3.4 nM when using B-Raf as its activator. [1] It is highly selective over broad inhibitory panel of 98 kinases at 10 uM. In vitro, Trametinib strongly inhibits human colorectal cancer cell lines known to have a constitutively active B-Raf or Ras mutation; in particular, IC50 inhibition values of HT-29, COLO205, HCT116, LS-174T, and SW620 are 0.48, 0.52, 5.7, 4.1, and 2.3 nM, respectively. [1]

Trametinib prevents Raf-dependent MEK phosphorylation (S217 for MEK1), resulting in prolonged p-Erk1/2 inhibition. [2] In a broad panel of cancer cell lines, Trametinib was shown to inhibit the MEK1/2-dependent activating dual phosphorylation of ERK1/2 on both T202 and Y204.

Trametinib has been shown to work in combination with other B-Raf inhibitors, overcoming resistant lines mediated by NRAS or MEK mutations. [3]

Technical information:

Chemical Formula:   C26H23FIN5O4
CAS #:   871700-17-3
Molecular Weight:   615.39
Purity:   > 98%
Appearance:   White
Chemical Name:   N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide
Solubility:   Up to 10 mM in DMSO
Synonyms:   GSK-1120212, GSK1120212, JTP-74057, Trametinib

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Yamaguchi et al., Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int. J. Oncol. 2011, 39(1), 23-31. Pubmed ID: 21523318
2. Gilmartin et al., GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 2011, 17, 989-1000. Pubmed ID: 21245089
3. Greger et al., Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 2012, 11(4), 909-920. Pubmed ID: 22389471

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the GSK1120212 (Trametinib) | MEK1/2 inhibitor to your wish list.

You Recently Viewed...